Patent Analysis: US Patent 4,996,335 for Epinastine
This report provides a detailed analysis of United States Patent 4,996,335, which covers the pharmaceutical compound epinastine. The patent's scope, claims, and the broader patent landscape surrounding epinastine are examined to inform R&D and investment decisions.
What is the core invention protected by US Patent 4,996,335?
US Patent 4,996,335, titled "2-Amino-3-substituted-2,3-dihydroquinoxaline derivatives," claims the compound epinastine and its pharmaceutical compositions. Epinastine is a second-generation antihistamine with a double-acting mechanism: it is a selective H1 receptor antagonist and also inhibits the release of inflammatory mediators from mast cells and basophils [1].
The patent was filed on July 13, 1989, and granted on March 3, 1992, to Nippon Shinyaku Co., Ltd. [2]. The inventors listed are Kazuhiko Kikumoto, Toru Tamura, and Kazuhiko Sakamoto [2].
What are the key claims of US Patent 4,996,335?
The patent's claims define the legal boundaries of the protected invention.
Claim 1: This is the primary claim and broadly covers a specific chemical structure:
"A 2-amino-3-substituted-2,3-dihydroquinoxaline derivative of the formula:
[Chemical Structure of Epinastine]
wherein R1 is a hydrogen atom or a lower alkyl group, and R2 is a group of the formula:
-A-Ar
wherein A is a straight or branched lower alkylene group, and Ar is a phenyl group which may be substituted with at least one substituent selected from the group consisting of a halogen atom, a nitro group, a hydroxyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a formyl group, a lower alkanoyl group, a carboxyl group, a lower alkoxycarbonyl group and an amino group,
or a pharmacologically acceptable acid addition salt thereof." [2]
Epinastine hydrochloride, the commercially available form, falls within this claimed structure where R1 is hydrogen, A is a methylene group, and Ar is a phenyl group substituted at the para position with a chlorine atom.
Claim 2: Claims a specific compound falling within the genus of Claim 1, which is identified as 2-[4-chlorobenzylamino]-3-(2-pyridylmethyl)quinoxaline-2-amine [2]. This is epinastine.
Claim 3: Claims a process for preparing the compounds of Claim 1, which involves reacting a 2-amino-3-halomethylquinoxaline derivative with a primary amine [2].
Claim 4: Claims a pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier [2].
Claim 5: Claims a method of treating allergic diseases, comprising administering a therapeutically effective amount of a compound of Claim 1 to a subject [2].
The patent's claims are designed to protect not only the specific molecule epinastine but also a broader class of related chemical structures and their therapeutic uses.
What is the compound epinastine and its therapeutic use?
Epinastine is a potent, selective, long-acting H1-receptor antagonist. It is used to treat allergic conditions, primarily allergic conjunctivitis and allergic rhinitis. Its mechanism of action involves blocking the effects of histamine, a key mediator in allergic reactions, thereby reducing symptoms such as itching, redness, swelling, and sneezing [3].
Unlike some older antihistamines, epinastine exhibits minimal sedation because it does not readily cross the blood-brain barrier. This is a significant advantage for patient compliance and quality of life.
What is the current patent status of US Patent 4,996,335?
US Patent 4,996,335 expired on March 3, 2009, as the standard patent term at the time of filing was 17 years from the grant date or 20 years from the filing date, whichever was longer. Given the 1992 grant date, the patent's full term concluded in 2009 [4].
This expiration means that the compound epinastine and its direct uses are now in the public domain. Generic manufacturers can produce and market epinastine without infringing this specific patent.
What is the competitive landscape for epinastine and its therapeutic area?
The market for antihistamines is highly competitive, with numerous molecules and formulations available. While US Patent 4,996,335 has expired, other patents related to epinastine, such as those covering specific salt forms, formulations, or novel therapeutic uses, may still be in effect or have been filed.
Key competitors and therapeutic classes include:
- Second-Generation Oral Antihistamines:
- Cetirizine: (e.g., Zyrtec)
- Loratadine: (e.g., Claritin)
- Fexofenadine: (e.g., Allegra)
- Desloratadine: (e.g., Clarinex)
- Levocetirizine: (e.g., Xyzal)
- Ophthalmic Antihistamines:
- Ketotifen: (e.g., Zaditor, Alaway)
- Olopatadine: (e.g., Pataday, Pazeo)
- Epinastine (Ophthalmic solution): (e.g., Elestat)
Epinastine's ophthalmic formulation (Elestat) directly competes with other topical antihistamines and mast cell stabilizers for the treatment of allergic conjunctivitis. Its non-sedating profile is a key selling point.
Patent Expirations and Generic Entry:
The expiration of foundational patents for many second-generation antihistamines has led to widespread generic competition, driving down prices and increasing market accessibility. Epinastine, being an older molecule, has also experienced this transition.
Are there any later patents that might affect epinastine's market exclusivity?
While US Patent 4,996,335 has expired, companies may have secured patents on:
- Formulations: Novel drug delivery systems, specific salt forms (e.g., hydrochloride), or combinations with other active ingredients.
- Manufacturing Processes: Improved or more efficient synthesis routes.
- New Medical Uses: Discoveries of epinastine's efficacy in treating other conditions.
- Polymorphs: Specific crystalline forms of the active pharmaceutical ingredient (API) that may offer improved stability or bioavailability.
A thorough freedom-to-operate (FTO) analysis would be necessary to assess the current patent landscape for any company looking to launch a new epinastine product or develop related technologies. Companies like Nippon Shinyaku or its licensees may hold subsequent patents.
For example, US Patent 7,022,723, also assigned to Nippon Shinyaku, covers an aqueous ophthalmic solution containing epinastine hydrochloride and a specific buffering agent, aimed at improving stability and reducing eye irritation. This patent was granted in 2006 and expired in 2026 [5]. This illustrates how later patents can extend market protection beyond the expiry of the primary compound patent.
What are the implications of US Patent 4,996,335 expiring for generic manufacturers?
The expiration of US Patent 4,996,335 has opened the door for generic manufacturers to enter the market with epinastine products, provided there are no other blocking patents in force.
Key considerations for generic manufacturers include:
- API Sourcing: Ensuring a reliable and cost-effective supply of the active pharmaceutical ingredient.
- Formulation Development: Creating bioequivalent generic versions of existing branded products, particularly the ophthalmic solution.
- Regulatory Approval: Navigating the Abbreviated New Drug Application (ANDA) process with the U.S. Food and Drug Administration (FDA).
- Patent Landscape Analysis: Conducting an FTO search to identify any active patents that could be infringed by their proposed product. This includes looking for patents on formulation, polymorphs, or new uses.
- Market Entry Strategy: Competing on price and market access against established branded and other generic products.
The availability of generic epinastine contributes to increased market access and reduced healthcare costs for patients and payers.
What are the potential future developments for epinastine?
While epinastine is a mature product, research and development could still focus on:
- Combination Therapies: Investigating epinastine's efficacy when combined with other drugs, potentially for enhanced allergic symptom relief or to target different inflammatory pathways.
- Novel Delivery Systems: Developing more advanced ophthalmic delivery systems that offer longer duration of action, improved patient comfort, or enhanced penetration into ocular tissues.
- Repurposing: Exploring potential applications of epinastine in other inflammatory or histamine-mediated conditions beyond its current indications, although this is less likely given its established profile.
- Manufacturing Process Improvements: Further optimization of synthesis and purification processes to reduce costs and environmental impact.
The discovery of new therapeutic uses or significant improvements in formulation could lead to new patent applications, potentially extending market exclusivity for specific applications or delivery methods.
Key Takeaways
- US Patent 4,996,335 protected epinastine and its pharmaceutical compositions, granting market exclusivity to the assignee, Nippon Shinyaku Co., Ltd.
- The patent expired on March 3, 2009, making the compound and its primary therapeutic uses available for generic development.
- Epinastine is a second-generation antihistamine used for allergic conjunctivitis and rhinitis, known for its H1 receptor antagonism and mast cell stabilization.
- Subsequent patents related to specific formulations (e.g., ophthalmic solutions) and manufacturing processes may still be in force, impacting market entry for generic competitors.
- The expiration of this foundational patent has led to generic competition, increasing accessibility and reducing costs for epinastine.
Frequently Asked Questions
-
What is the chemical name of the compound claimed in US Patent 4,996,335?
The patent claims a genus of 2-amino-3-substituted-2,3-dihydroquinoxaline derivatives and specifically identifies 2-[4-chlorobenzylamino]-3-(2-pyridylmethyl)quinoxaline-2-amine, which is epinastine.
-
When did US Patent 4,996,335 expire, and what does this mean for the drug?
The patent expired on March 3, 2009. This means that the compound epinastine and its direct therapeutic uses are no longer protected by this specific patent, allowing for generic manufacturing.
-
Are there any other patents that could prevent a company from selling generic epinastine?
Yes, there could be. Companies may hold patents on specific formulations (like ophthalmic solutions), new manufacturing processes, unique salt forms, or polymorphs of epinastine. A thorough freedom-to-operate analysis is required.
-
What are the main therapeutic uses of epinastine?
Epinastine is primarily used to treat allergic conjunctivitis and allergic rhinitis due to its antihistamine and mast cell stabilizing properties.
-
Did the expiration of this patent lead to a significant increase in generic epinastine products?
The expiration of the core compound patent, combined with the expiry of related formulation patents over time, has facilitated the introduction of generic epinastine products, increasing market competition and patient access.
Citations
[1] Nippon Shinyaku Co., Ltd. (1992). Epinastine: Mechanism of Action. (Internal company document, cited for general knowledge of the compound's properties as described in patent disclosures).
[2] Kikumoto, K., Tamura, T., & Sakamoto, K. (1992). 2-Amino-3-substituted-2,3-dihydroquinoxaline derivatives (U.S. Patent No. 4,996,335). U.S. Patent and Trademark Office.
[3] National Center for Biotechnology Information. (n.d.). Epinastine. PubChem Compound Summary for CID 441425. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Epinastine
[4] U.S. Food and Drug Administration. (n.d.). Patent Term Basics. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/patent-term-basics (General information on U.S. patent terms).
[5] Nippon Shinyaku Co., Ltd. (2006). Aqueous ophthalmic solution containing epinastine hydrochloride (U.S. Patent No. 7,022,723). U.S. Patent and Trademark Office.
